Carnie Lindsay E, Shah Dinakshi, Vaughan Kate, Kapacee Zainul Abedin, McCallum Lynne, Abraham Marc, Backen Alison, McNamara Mairéad G, Hubner Richard A, Barriuso Jorge, Gillespie Loraine, Lamarca Angela, Valle Juan W
Nutrition & Dietetics, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
Cancers (Basel). 2023 Apr 13;15(8):2277. doi: 10.3390/cancers15082277.
Pancreatic exocrine insufficiency (PEI) in patients with advanced pancreatic cancer (aPC) is well documented, but there is no consensus regarding optimal screening.
Patients diagnosed with aPC referred for palliative therapy were prospectively recruited. A full dietetic assessment (including Mid-Upper Arm Circumference (MUAC), handgrip and stair-climb test), nutritional blood panel, faecal elastase (FE-1) and C-mixed triglyceride breath tests were performed.
prevalence of dietitian-assessed PEI (demographic cohort (De-ch)); design (diagnostic cohort (Di-ch)) and validation (follow-up cohort (Fol-ch)) of a PEI screening tool. Logistic and Cox regressions were used for statistical analysis.
Between 1 July 2018 and 30 October 2020, 112 patients were recruited (50 (De-ch), 25 (Di-ch) and 37 (Fol-ch)). Prevalence of PEI (De-ch) was 64.0% (flatus (84.0%), weight loss (84.0%), abdominal discomfort (50.0%) and steatorrhea (48.0%)). The derived PEI screening panel (Di-ch) included FE-1 (normal/missing (0 points); low (1 point)) and MUAC (normal/missing (>percentile 25) (0 points); low (2 points)) and identified patients at high-risk (2-3 total points) of PEI [vs. low-medium risk (0-1 total points)]. When patients from the De-ch and Di-ch were analysed together, those classified by the screening panel as "high-risk" had shorter overall survival (multivariable Hazard Ratio (mHR) 1.86 (95% CI 1.03-3.36); -value 0.040). The screening panel was tested in the Fol-ch; 78.4% patients classified as "high-risk", of whom 89.6% had dietitian-confirmed PEI. The panel was feasible for use in clinical practice (64.8% patients completed all assessments), with high acceptability (87.5% would repeat it). Most patients (91.3%) recommended dietetic input for all patients with aPC.
PEI is present in most patients with aPC; early dietetic input provides a holistic nutritional overview, including, but not limited to, PEI. This proposed screening panel may help to prioritise those at higher risk of PEI, requiring urgent dietitian input. Its prognostic role needs further validation.
晚期胰腺癌(aPC)患者中胰腺外分泌功能不全(PEI)已有充分记录,但关于最佳筛查方法尚无共识。
前瞻性招募接受姑息治疗的aPC确诊患者。进行全面的饮食评估(包括上臂中部周长(MUAC)、握力和爬楼梯测试)、营养血液指标检测、粪便弹性蛋白酶(FE-1)和C-混合甘油三酯呼气试验。
营养师评估的PEI患病率(人口队列(De-ch));PEI筛查工具的设计(诊断队列(Di-ch))和验证(随访队列(Fol-ch))。采用逻辑回归和Cox回归进行统计分析。
2018年7月1日至2020年10月30日期间,共招募112例患者(50例(De-ch)、25例(Di-ch)和37例(Fol-ch))。PEI(De-ch)的患病率为64.0%(肠胃胀气(84.0%)、体重减轻(84.0%)、腹部不适(50.0%)和脂肪泻(48.0%))。推导得出的PEI筛查指标(Di-ch)包括FE-1(正常/缺失(0分);低水平(1分))和MUAC(正常/缺失(>第25百分位数)(0分);低水平(2分)),并识别出PEI高风险患者(总分2 - 3分)[与低 - 中风险患者(总分0 - 1分)相比]。当对De-ch和Di-ch的患者进行综合分析时,筛查指标分类为“高风险”的患者总生存期较短(多变量风险比(mHR)1.86(95%置信区间1.03 - 3.36);P值0.040)。该筛查指标在Fol-ch中进行了测试;78.4%的患者被分类为“高风险”,其中89.6%的患者经营养师确认患有PEI。该指标在临床实践中可行(64.8%的患者完成了所有评估),且接受度高(87.5%的患者愿意重复检测)。大多数患者(91.3%)建议对所有aPC患者提供饮食指导。
大多数aPC患者存在PEI;早期饮食指导可提供全面的营养概况,包括但不限于PEI。这一提出的筛查指标可能有助于确定PEI高风险患者,这些患者需要紧急的营养师指导。其预后作用需要进一步验证。